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Simple Summary: MicroRNAs play pivotal roles in skeletal muscle development, but the molecular
basis of their functions in fetal bovine skeletal muscle development is largely unknown. Here,
we report a mechanistic study of bta-miR-24-3p, a key miRNA regulator of the myogenic
differentiation of fetal bovine platelet-derived growth factor receptor alpha PDGFRα- progenitor
cells. We isolated progenitor cells from the bovine fetal longissimus dorsi muscle and purified
them with PDGFRα antibodies to remove fibro-adipogenic progenitors. We observed elevated
bta-miR-24-3p expression during differentiation, and bta-miR-24-3p overexpression led to promoted
myogenic differentiation but suppressed proliferation. Moreover, activin receptor type 1B (ACVR1B)
was identified as a direct target of bta-miR-24-3p, and ACVR1B-silencing cells exhibited similar
phenotypes to bta-miR-24-3p-overexpressing bovine PDGFRα- progenitor cells. These results extended
our understanding on the roles of miRNA in fetal muscle development. The method of removing
fibro-adipogenic progenitors in our study will also provide useful information for other investigators.
Abstract: MicroRNAs modulate a variety of cellular events, including skeletal muscle development,
but the molecular basis of their functions in fetal bovine skeletal muscle development is poorly
understood. In this study, we report that bta-miR-24-3p promotes the myogenic differentiation of
fetal bovine PDGFRα- progenitor cells. The expression of bta-miR-24-3p increased during myogenic
differentiation. Overexpression of bta-miR-24-3p significantly promoted myogenic differentiation,
but inhibited proliferation. A dual-luciferase assay identified ACVR1B as a direct target of
bta-miR-24-3p. Similarly, knocking down ACVR1B by RNA interference also significantly inhibited
proliferation and promoted the differentiation of bovine PDGFRα- progenitor cells. Thus, our study
provides a mechanism in which bta-miR-24-3p regulates myogenesis by inhibiting ACVR1B expression.
Keywords: bta-miR-24-3p; bovine; fetal skeletal muscle; proliferation; differentiation; ACVR1B
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1. Introduction
The fetal stage is crucial for skeletal muscle development, because the majority of skeletal muscle
fibers form during this stage [1]. Skeletal muscle growth and development involve a series of complex
biological processes regulated by myogenic regulatory factors (MRFs) [2]. For example, myogenic
factor 5 (Myf5) and myogenic differentiation 1 (MyoD) are critical for the commitment, proliferation,
and survival of myoblasts, whereas myogenin (MyoG) and myogenic factor 6 (Myf6) play essential roles
in terminal differentiation [3–5]. Myogenic differentiation is also regulated at the post-transcriptional
level, such as with microRNAs (miRNAs).
MicroRNAs (miRNAs) are endogenous, non-coding RNAs (ncRNA) of 20–24 nucleotides, and
suppress translation via binding to the 3′-untranslated region (3′-UTR) of their target mRNAs [6,7].
It has been reported that miRNAs regulate muscle development [8,9]. For example, miR-143 regulates
bovine muscle satellite cell (MSCs) differentiation and proliferation by directly targeting insulin like
growth factor binding protein 5 (IGFBP5) [10]. miR-148-3p could inhibit the proliferation and enhance
the apoptosis of bovine muscle cells by targeting Kruppel like factor 6 (KLF6) [11]. bta-miR-378 could
promote bovine skeletal muscle-derived satellite cell (bMDSC) differentiation by suppressing DNA
polymerase alpha 2 (POLA2) expression [12]. These findings point to a role of miRNAs in bovine
skeletal muscle development.
bta-miR-24-3p is 22 nt in length and is derived from its precursor miRNA bta-miR-24-2. miR-24
is upregulated during myogenesis and promotes myogenic differentiation through an unknown
mechanism [13]. According to published data, miR-24-3p hampers skeletal muscle fibrosis by interacting
with its target, Smad2, which is involved in transforming growth factor-β (TGFβ)/Smad signaling [14].
However, the regulatory role of bta-miR-24-3p in the prenatal development of bovine skeletal muscle
is still not clear.
Activin receptor type 1B (ACVR1B, also known as ALK4) encodes a transducer of activin or
activin-like ligand signals. It is known to participate in embryonic development, nervous system
differentiation, germ cell development, tumor formation, and immunosuppression [15–17]. ACVR1B
influences myogenesis and regulates the balance between protein synthesis and degradation by
modulating the MSTN pathway to maintain muscle mass [18]. In addition, miR-210 regulates
transforming growth factor-β (TGF-β)/activin signaling to promote osteoblastic differentiation by
targeting ACVR1B [19]. A study with ACVR1B-knockout mice provided evidence for a specific and
indispensable role of ACVR1B signaling in the cycling and differentiation of hair follicle and tooth
morphogenesis [20]. However, the role of ACVR1B in fetal bovine myogenesis and proliferation,
and whether it is regulated by miRNAs in the differentiation and proliferation of skeletal muscle,
is still unknown.
In this study, we purified myogenic progenitor cells using antibodies of platelet-derived growth
factor receptor alpha (PDGFRα), which is the cell surface marker of fibro/adipogenic lineages [21],
and named the cells as PDGFRα- progenitor cells. This study investigates the underlying molecular
basis of how miR-24-3p modulates the differentiation and proliferation of fetal bovine skeletal,
muscle-derived progenitor cells. Moreover, we predicted the potential targets of bta-miR-24-3p and
experimentally demonstrated its regulatory mechanism. The effect of ACVR1B on the differentiation
and proliferation of fetal bovine skeletal muscle-derived progenitor cells was also explored. Our results
demonstrate that bta-miR-24-3p inhibits bovine PDGFRα- progenitor cell proliferation and improves
their differentiation by targeting ACVR1B. This research provides insight into the epigenetic regulation
of skeletal muscle development during the fetal stage.
2. Materials and Methods
2.1. Ethics Statement
All animal experiments followed the guidelines of the Regulations for the Administration of Affairs
Concerning Experimental Animals (Ministry of Science and Technology, China, 2004). All animal
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experimental protocols in this study were strictly monitored by the Animal Ethics Committee of the
Institute of Animal Sciences, Chinese Academy of Agricultural Sciences (IAS-CAAS). Ethical approval
of animal survival was given by the animal ethics committee of IAS-CAAS (No. IAS2019-48). Pregnant
cows were raised at the Inner Mongolia Aokesi Agriculture Co., Ltd. (Wulagai, China). Efforts were
made to minimize the cows’ suffering.
2.2. Primary Cell Isolation and Cell Culture
The progenitor cells were enzymatically isolated from longissimus dorsi tissues obtained from
three male bovine fetuses about 90–120 days after conception, as described previously [22]. Briefly,
longissimus dorsi was minced into small fragments and then incubated with 0.1% type IV collagenase
(Sigma, St. Louis, MO, USA) for 1 h. This enzymatic digestion was terminated by adding cell culture
medium containing low-glucose DMEM (Dulbecco’s Modified Eagle medium; Gibco, Grand Island, NY,
USA), supplemented with 10% FBS (fetal bovine serum; Gibco, Grand Island, NY, USA). The digested
tissue suspension was passed through a nylon mesh (40 µm pore size), and the pellets were obtained
by centrifuging and resuspending in ice-cold phosphate-buffered saline (PBS) buffer containing 2 mM
EDTA and 0.5% bovine serum albumin. The cell suspension was incubated with anti-PDGFRα antibody
(Cell Signaling Technology, Danvers, MA, USA) at 4 ◦C for 30 min. After washing and resuspending in
PBS, the cells were incubated with Anti-Rabbit IgG MicroBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) at 4 ◦C for 15 min. Subsequently, the cells were harvested and resuspended in the buffer.
PDGFRα- cells were separated by a MACS column (Miltenyi Biotec) and magnetic MiniMACS Separator
(Miltenyi Biotec). These cells were cultured in DMEM supplemented with 10% FBS and maintained at
37 ◦C with a 5% CO2 atmosphere. The cells from each fetus were maintained separately. The cells
were passaged with 0.25% trypsin-EDTA (Gibco, Grand Island, NY, USA) at 70–80% confluence and
induced in the differentiation medium (DM) containing Dulbecco’s modified Eagle’s medium (DMEM,
Gibco, Grand Island, NY, USA) and 5% horse serum when reaching 100% confluence.
DMEM was used to culture HEK293, a human embryonic kidney cell line. The medium contains
high glucose, 100 U/mL penicillin, 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA),
and 100 µg/mL streptomycin at 37 ◦C and 5% CO2.
2.3. RNA Isolation, Reverse Transcription (RT), and Quantitative Real-Time PCR (qRT-PCR)
Total RNA was isolated from the cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
RNA concentration and quality were assessed by a NanoPhotometer N50 (Implen, Munich, Germany)
and 1.5% agarose gel electrophoresis. We synthesized first-strand cDNA by reverse-transcribing the
isolated total RNA using PrimeScript RT Master Mix (Perfect Real Time) (TaKaRa, Kusatsu, Japan).
For MicroRNA, the reverse transcripts were obtained with a miRcute Plus miRNA First-Stand cDNA
Synthesis Kit (KR211, TIANGEN, Beijing, China). Then quantitative real-time PCR (qRT-PCR) was
performed by the QuantStudio 7 Flex Real-Time PCR System (Life, Carlsbad, CA, USA), with the KAPA
SYBR® FAST qPCR Kit (KAPABiosystems, Wilmington, MA, USA) and a miRcute Plus miRNA qPCR
Kit (FP411, TIANGEN). All assays were performed following the manufacturer’s recommendations.
Three technical replicates were used for all reactions. The sequences of miRNA-specific and qRT-PCR
primers are summarized in Table 1.
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Table 1. Primers used for quantitative real-time PCR (qRT-PCR).









Cyclin D1 GACGAGCTGCTGCACATGGA TGCTTGTTCTCCTCGGCCAC




MyoG: myogenin; MYH: myosin heavy chain; PCNA: proliferating cell nuclear antigen; CDK2: cyclin-dependent
kinase 2; CDKN1A: cyclin-dependent kinase inhibitor 1A.
2.4. Immunofluorescence
For immunofluorescence, the cells were cultured in 12-well plates, fixed in 4% paraformaldehyde
for 15 min, and washed three times (five min each) with PBS. Next, we permeabilized the cells
with 0.1% Triton X-100 for 10 min and blocked the cells with 1% albumin bovine serum (Beyotime,
Shanghai, China) for 30 min. After incubation with the anti-myosin heavy chain (MHC) antibody (1:100,
Developmental Studies Hybridoma Bank, Iowa, USA) overnight at 4 ◦C, FITC-labeled Goat Anti-Mouse
IgG (H + L) (1:1000, Beyotime) was added, and the cells were incubated at room temperature for 1 h.
The cell nuclei were stained with DAPI (Sigma-Aldrich, St. Louis, MO USA) for 5 min, and images
were obtained with a confocal microscope (TCS SP8, Leica, Wetzlar, Germany).
2.5. Western Blot
The cells were lysed with proteinase inhibitors, and protein samples of equal amount were
separated on 4–12% SurePAGE gels (GenScript, Nanjing, China). The proteins were transferred to
nitrocellulose membranes (Pall, Mexico) after electrophoresis and blocked in 5% (w/v) non-fat milk. The
membranes were incubated with the ACVR1B (1:3000, Proteintech, Chicago, IL, USA), MyoG (1:1000,
Santa Cruz, Delaware Ave Santa Cruz, CA, USA), MHC (1:50, Developmental Studies Hybridoma
Bank), and β-tubulin (1:2000, Proteintech) antibodies—all of which are primary antibodies—at 4 ◦C
overnight, washed three times with saline/Tween (in Tris), and incubated with HRP-labeled Goat
Anti-Mouse IgG (1:1000, Beyotime) or HRP-labeled Goat Anti-Rabbit IgG (1:1000, Beyotime) at room
temperature for 1 h. ECL western blotting detection reagent (Beyotime) was used to visualize the
protein bands.
2.6. 5-Ethynyl-2′-deoxyuridine (EdU) Assay
The cells were cultured until 50% density and transfected with the miR-24-3p mimic, the mimic
NC, the ACVRIB siRNA (si-ACVR1B), and the siRNA negative control (si-NC). The cells were subjected
to the 5-Ethynyl-2’-deoxyuridine (EdU) assay 24 h after transfection using an EdU Apollo In Vitro
Imaging Kit (RiboBio, Guangzhou, China). We captured three randomly selected fields using a
fluorescence microscope (TCS SP8, Leica) and determined the number of EdU-stained cells. ImageJ
was used to determine the percentage of EdU-positive cells.
2.7. Cell Counting Kit-8 (CCK8) Assay
The cells were cultured in 96-well plates and transfected with the miR-24-3p mimic or the mimic
NC. After 24, 48, 72, and 96 h of transfection, a 10 µL Cell Counting Kit-8 reagent (Beyotime) was
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added into each well and incubated for 1 h. Optical absorption at 450 nm (A450) was measured by
an Imark Microplate Reader (Bio-Rad), and the average A450 values of six independent experiments
were calculated.
2.8. RNA Oligonucleotide Preparation and Cell Transfection
The bta-miR-24-3p mimics, the mimic NC, the siRNAs used to knockdown ACVR1B, and the
non-specific siRNA negative control were designed and synthesized by RiboBio (Guangzhou, China).
The si-ACVR1B sequence is 5’-CGCTGACAATAAAGATAAC-3’. Transfection was performed with
the Lipofectamine RNAiMAX reagent (Invitrogen). All procedures were performed according to the
manufacturers’ protocols.
2.9. Prediction of miRNA Target Genes
The miRNA target gene prediction was performed by TargetScanHuman 7.2 (http://www.
targetscan.org/vert_72/).
2.10. Dual-Luciferase Reporter Assay
The binding site of bta-miR-24-3p in ACVR1B was amplified from bovine DNA and inserted into
the psi-CHECK2 vector (Promega, Madison, WI, USA) via XhoI and NotI double digestion. Site-directed
mutagenesis of the resulting construct was performed using the Fast Site-Directed Mutagenesis Kit
(TIANGEN) to remove the potential binding site. Refer to Table 2 for details on primers used in
plasmid construction and mutagenesis.
Table 2. Primers used for vector construction.
Name Forward (5’–3’) Reverse (5’–3’)
Psi-CHECK-ACVR1B-W ACTCTCGAGAACAACCACACACACAAAA ATAGCGGCCGCGGATGAGAAGGTGCAACTT
Psi-CHECK-ACVR1B-Mut TATCTGTCCTTGTACTGCTCCCCCCCGCCC GGGCGGGGGGGAGCAGTACAAGGACAGATA
For luciferase reporter assays, HEK293T cells were co-transfected with bta-miR-24-3p mimics
(or the mimic NC) and the wild-type or mutant psi-CHECK2 plasmid, using the Lipofectamine 3000
reagent (Invitrogen). Luciferase activity was determined by the Dual-Luciferase Reporter Assay System
(Promega) 48 h after transfection.
2.11. Statistical Analysis
At least three technical replicates were used for statistical analysis. The Normality of the data was
verified by Student’s t-test using GraphPad Prism (version 6.0, GraphPad Software, San Diego, CA,
USA); p < 0.05 was considered statistically significant.
3. Results
3.1. Bta-miR-24-3p Is Up-Regulated During the Myogenic Differentiation of PDGFRα- Progenitor Cells
To investigate the expression of bta-miR-24-3p during myogenesis, PDGFRα- progenitor cells
were isolated from the longissimus dorsi tissue of bovine fetus, according to a previous study [21],
and then myogenic differentiation was induced in vitro. The PDGFRα- progenitor cells formed
obvious myotubes two days after myogenic induction (Figure 1A,B). Moreover, immunostaining
of muscle-specific protein showed that MyoG was downregulated during myogenic differentiation,
whereas myosin heavy chain (MHC) was upregulated (Figure 1C). We then determined the transcript
levels of the MYH genes during myogenic differentiation, and found that the MYH1, MYH2 and MYH4
expression increased, whereas that of MYH7 decreased two days after differentiation (Figure 1D). In
addition, a gradual increase in bta-miR-24-3p expression was observed during myogenic differentiation
(Figure 1E).
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= 100 μm. (B) Myosin heavy chain (MHC)-positive cells (green) on D0, D2, D3, and D5 of myogenic 
differentiation, visualized by immunofluorescence; scale bars = 100 μm. (C) Western blot evaluating 
the protein levels of myogenin and MHCs in cells cultured, as described in A. (D) Transcript levels of 
myogenin and MHCs in cells cultured, as described in (A). (E) The transcript level of bta-miR-24-3p 
in cells cultured, as described in (A). All data are represented as mean ± standard deviation (SD), 
based on at least three independent experiments for each treatment. 
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transcript analysis, significantly higher levels of MyoG and MHC proteins were observed in the 
mimic group than in the NC group (Figure 2C). The immunofluorescence assay showed that bta-
miR-24-3p mimics significantly increased the total number of MHC-positive cells at the end of 
myogenic differentiation, as compared with the control group (Figure 2D). Taken together, these 
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Figure 1. bta-miR-24-3p expression during the myogenic differentiation of platelet-derived growth factor
receptor alpha (PDGFRα-) progenitor cells. (A) Microscopic images of bovine PDGFRα- progenitor
cells on days 0, 2, 3, and 5 (D0, D2, D3, and D5, respectively) of differentiation. Scale bars = 100 µm.
(B) Myosin heavy chain (MHC)-positive cells (green) on D0, D2, D3, and D5 of myogenic differentiation,
visualized by immunofluorescence; scale bars = 100 µm. (C) Western blot evaluating the protein levels
of myogenin and MHCs in cells cultured, as described in A. (D) Transcript levels of myogenin and
MHCs in cells cultured, as described in (A). (E) The transcript level of bta-miR-24-3p in cells cultured,
as described in (A). All data are represented as mean ± standard deviation (SD), based on at least three
independent experiments for each treatment.
3.2. Bta-miR-24-3p Promotes the Myogenic Differentiation of Bovine PDGFRα- Progenitor Cells
To investigate the potential roles of bta-miR-24-3p in bovine skeletal muscle myogenesis during
the fetal period, w transfected bta-miR-24-3p mimics a d the negative control (NC) into PDGFRα-
prog nitor cells. The levels of ma ure bta-miR-24-2 in the mimic group on day 2 and day 5 were 30-
and 19-fold higher than those in the NC group, respectively (Figure 2A). bta-miR-24-3p accumulation
led to a significant increase in the transcript levels of myogenic differentiation arker genes, including
MyoG, MYH1, MYH2, MYH4, and MYH7 (Figure 2B). Consistent with the results of transcript analysi ,
significantly higher levels of MyoG and MHC proteins were observed in the mimic group than in the
NC group (Figure 2C). The immunofluorescence assay showed that bta-miR-24-3p mimic significantly
increased the tot l numb r of MHC- ositive cells at t end of myogeni differentiation, as compared
with the control group (Figure 2D). Taken tog ther, these results point to a role of bta-miR-24-3p in
promoting myog ic differentiation.
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results demonstrate the inhibitory effect of bta-miR-24-3p on bovine PDGFRα- progenitor cell 
proliferation. 
Figure 2. The expression of bta-miR-24-3p during the myogenic differentiation of bovine PDGFRα-
progenitor cells. (A) bta-miR-24-3p expression 48 h after miR-24-3p mimics transfection, determined
by qRT-PCR. (B) Transcript levels of myogenin and MHCs detected by qRT-PCR on D2 and
D5. (C) Western blot evaluating the protein levels of myogenin and MHC 96 h following
differentiation. (D) MHC-positive cells (green) on D2 and D5 of myogenic differentiation, visualized
by immunofluorescence. Scale bars represent 100 µm. All data are represented as mean ± standard
deviation (SD,) based on at least three independent experiments for each treatment. * p < 0.05
and ** p < 0.01.
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assay and CCK8 as ay were used to analyze the proliferation of cells transfected by miR-24-3p
mi ics or NC. The EdU assays showed that miR-24-3p overexpres ion significantly decreased t
roportion of EdU-positive cells (Figure 3A). The CCK8 assay revealed that miR-24-3p overexpression
inhibited bovi e PDGFRα- progenitor cell prolif rati n (Figure 3B). In addition, the transcript levels
of cy lin D1, cyclin B1, proliferating cell nuclear antigen (PCNA), and cyclin-dependent kinase 2
(CDK2)—all of which are cell cycle-promoting genes—we e decreased upon miR-24-3p overexpression.
Conversely, miR-24-3p overexpression promotes the expres ion of the cell proliferation-inhibiting gene
cyclin-depe dent kinase inhibitor 1A (CDKN1A) (Figure 3C). These results demonstrate the inhibitory
effect of bta-miR-24-3p on bovine PDGFRα- progenitor cell proliferation.
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Figure 3. The effect of miR-24-3p on bovine PDGFRα- progenitor cell proliferation. (A) EdU staining
of the PDGFRα- progenitor cells after the transfection of miR-24-3p mimics and EdU-positive cell
determination. (B) Cell Counting Kit-8 (CCK8) assay showing that miR-24-3p mimics inhibit PDGFRα-
progenitor cell proliferation. (C) The relative transcript levels of cell cycle-related genes after transfection.
Scale bars = 100 µm. All data are represented as mean ± standard deviation (SD), based on at least
three independent experiments for each treatment. * p < 0.05 and ** p < 0.01.
3.4. ACVR1B Is a Direct Target of Bta-miR-24-3p
To further explore the molecular mechanism of how bta-miR-24-3p regulates bovine myogenesis,
we predicted miR-24-3p targets using the TargetScanHuman 7.2 databases (http://www.targetscan.org/
vert_72/). The seed sequence of bta-miR-24-3p perfectly matches the 3′ untranslated region (UTR) of
ACVR1B, suggesting that ACVR1B is a potential target of bta-miR-24-3p (Figure 4A). Furthermore,
we found that the potential binding site of bta-miR-24-3p was highly conserved among mam alian
ACVR1B genes (Figure 4B).
To verify the interaction between bta-miR-24-3p and ACVR1B, we inserted the fragment harboring
either the wild-type or mutated bta-miR-24-3p binding sequence in ACVR1B into a dual-luciferase
reporter vector. Each of the resulting constructs was separately introduced into 293T cells, along
with bta-miR-24-3p mimics, and luciferase activity was detected 48 h after transfection. We detected
significantly decreased luciferase activity in 293T cells expressing the wild-type ACVR1B 3’ UTR
fragment, whereas that of 293T cells expressing the mutated fragment was not changed (Figure 4C).
This result suggests that the analyzed 3’ UTR sequence of ACVR1B is involved in bta-miR-24-3p
recognition. More importantly, compared with the control, we observed a significant reduction in the
ACVR1B transcript level in bovine PDGFRα- progenitor cells overexpressing bta-miR-24-3p (Figure 4D).
The protein level of ACVR1B in PDGFRα- progenitor cells was also decreased upon overexpressing
miR-24-2 mimics (Figure 4E). Collectively, these results demonstrate that ACVR1B is a direct target of
bta-miR-24-3p in bovine PDGFRα- progenitor cells.
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reporter. (B) Sequence alignment of the mature bta-miR-24-3p binding sites in seven different species.
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reporters linked to the wild-type or mutant bta-miR-24-3p binding sites. Relative luciferase activity was
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* p < 0.05 and ** p < 0.01.
3.5. ACVR1B Silencing Promotes Myogenic Differentiation But Inhibits Proliferation
To examine the role of ACVR1B in myogenic differentiation, we silenced the endogenous ACVR1B
in bovine PDGFRα- progenitor cells using small interfering RNA (siRNA). The interference efficiency
was verified, and the siRNA against ACVR1B (si-ACVR1B) significantly decreased the transcript and
protein levels of ACVR1B (Figure 5A). Moreover, a similar result was obtained on day 5 of myogenic
differentiation, when si-ACVR1B significantly upregulated the transcript levels of myogenesis marker
genes, MyoG, MYH1, MYH2, MYH4, and MYH7 (Figure 5B). Consistently, the protein levels of
MyoG and MHC in the myogenic differentiation increased upon ACVR1B knockdown (Figure 5B).
Furthermore, more multinuclear myotubes were observed in the knockdown group (Figure 5C).
The EdU assay revealed decreased number of EdU-positive cells in the si-ACVR1B group compared
with the control (Figure 5D), along with reduced Cyclin D1 and CDK2 but increased CDKN1A mRNA
levels (Figure 5E). Together, these findings suggest that knocking down ACVR1B significantly promotes
myogenic differentiation, but represses the proliferation of bovine PDGFRα- progenitor cells.
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4. Discussion
miR-24-2 is transcribed and processed from miR-23a/27a/24-2 clusters. It is suggested that
miR-24-2 is involved in many physiological and pathological processes, including cell differentiation,
proliferation, apoptosis, and metabolism, as well as disease occurrence [23–26]. miR-24-3p suppresses
apoptosis by targeting the Keap1-Nrf2 Pathway [27]. In lung cancer cells, miR-24-3p could promote
cell proliferation and migration; it also accelerates tumor growth in xenograft mice by directly
binding to SRY-box transcription factor 7 (SOX7) [28]. MiR-24 also participates in erythropoiesis [29].
miR-24-3p controls osteogenic differentiation via regulating SMAD family member 5 (Smad5) in
human periodontal ligament stem cells (hPDLSCs) [30]. Previous studies have demonstrated that
miR-24-3p can promote the proliferation of several types of cancer cells [25,31–35], which contradicts
our results. However, some studies have demonstrated that miR-24 could target high mobility group
box 1 (HMGB1) and inhibit the proliferation and migration of vascular smooth muscle cells [36].
These conflicting results may be mainly due to the differences in the cell types used. Also, miR-24
was found to inhibit proliferation by prohibiting or delaying the G1-to-S transition [37]. Although
the effect of miR-24-3p on proliferation and myogenic differentiation has been previously reported,
its target remains unclear. Here, we identified ACVR1B as a direct target of bta-miR-24-3p using an in
vitro model of fetal bovine myogenesis, and illustrated that bta-miR-24-3p inhibits proliferation and
promotes myogenic differentiation of progenitor cells by targeting ACVR1B.
ACVR1B is a member of the TGF-β pathway, which transduces extracellular signaling into the
cytoplasm [38]. TGF-β inhibits myogenesis through inhibiting the expression and function of MRFs.
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It has been shown that TGF-β reduces the expression of myogenin and myocyte enhancer factor
2D (MEF2D), as well as myotube formation in the C2C12 model via the Smad pathway, in a cell
density-dependent manner [39]. In addition, TGF-β induces MEF2 translocation from the nucleus
to the cytoplasm, thereby inhibiting MEF2 transcription [40]. It has also been demonstrated that
TGF-β inhibits myogenic differentiation via intracellular effector Smad3 in C3H10T1/2 and C2C12 cell
lines by repressing the activity of MyoD family members [41]. Moreover, TGF-β treatment inhibits
the transcriptional upregulation of p21 and muscle creatinine kinase (MCK) in C2C12 cells, which
are associated with growth arrest at the G1 phase and representative cell-lineage-specific expression
during myogenesis [42]. Furthermore, TGF-β could induce miRNAs, such as miR-206 and miR-29,
to control myogenic differentiation by regulating the expression of HDAC4 [43].
ACVR1B regulates the pluripotency and differentiation of stem cells in osteoclastogenesis,
myogenesis, and adipogenesis [44–46]. The activated type I receptor phosphorylates and thereby
activates specific Smads in the canonical signaling pathway, which enter into the nucleus to control the
gene transcriptional cascades [38,47,48]. Although several types of ligands share common receptors or
downstream Smads, they could fulfill their essential functions in vivo without interference from the
many other proteins of the superfamily. The ligands structure evolution enables distinct modes of
receptor binding, and engenders the TGF-βs with high specificity for their receptors [49]. The SMAD
complexes have weak affinity for DNA and limited specificity, and need cooperate with other
site-specific transcription factors [48]. The differences in the expression of these transcription factors
may contribute to the diverse effects of ACVR1B activation in different cell types.
In skeletal muscle, ACVR1B mediates the myostatin signaling, whose dysregulation is associated
with increased muscle mass in mammals [50–52]. Myostatin prefers ACVR1B in myoblasts, whereas it
utilizes ALK5 in non-myogenic cells [53]. In previous studies, myostatin has been demonstrated to
inhibit the myogenic differentiation of C2C12 cells [54,55]. ACVR1B inhibition promoted myogenetic
differentiation in C2C12 in vitro, and reduced muscle mass and muscle fiber size in ACVR1B-silencing
mice [18]. It is logical that miR-24-2 promotes differentiation by inhibiting ACVR1B expression to block
myostatin signaling. However, some contradictory results have been reported in previous research
studying the effect of myostatin on myogenic cell proliferation. Some studies have reported that
myostatin inhibits cell proliferation [55–58]. Another study reported that myostatin stimulates C2C12
myoblast proliferation [59]. Such a contradiction may be a result of the alteration in gene expression
caused by the immortalization process. Our study using cells freshly isolated from the fetal bovine
skeletal muscle very likely revealed the actual function of ACVR1B in myogenic cell proliferation [60].
Other members of the miR-23a/27a/24-2 cluster also regulate muscle development. For example,
miR-27a enhances myoblast differentiation, but the mechanism remains unclear [61]. Meanwhile, some
studies have found that miRNA-23a/27a inhibits muscle atrophy [62,63]. The similar functions observed
for miR-23a/27a/24-2 cluster members in myogenesis corroborate previous findings that miRNAs from
the same cluster evolved to regulate functionally-related genes in a coordinated manner [64]. In this
study, we demonstrate that bta-miR-24-3p accumulates and functions as a positive regulator during
myogenic differentiation of fetal bovine PDGFRα- progenitor cells.
5. Conclusions
Taken together, our findings reveal that bta-miR-24-3p promotes myogenic differentiation by
directly targeting and suppressing ACVR1B expression. Therefore, our findings on bta-miR-24-3p
and its target gene ACVR1B provide a mechanistic basis for related future research, and have great
potential in improving bovine skeletal muscle differentiation.
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